Drug Index

Cysteamine

Mechanism :

Reacts with cystine within the lysosome to convert it to cysteine and to a cysteine-cysteamine mixed disulfide, both of which can then exit the lysosome in patients with cystinosis, an inherited defect of lysosomal transport.


Indication :

  • Nephropathic cystinosis

Contraindications :

Hypersensitivity to cysteamine, penicillamine, or any component of the formulation.


Dosing :

Immediate Release Capsule
Initial: Give one-sixth to one-fourth of maintenance dose
Maintenance (<12 years): 1.3 g/m²/day or 60 mg/kg/day of free base PO divided q6hr; not to exceed 1.95 g/m²/day or 90 mg/kg/day.
Maintenance (≥12 years or >110 lbs): 2 g/day PO divided q6hr; dose should be reached after 4-6 weeks of incremental dosage increases; not to exceed 1.95 g/m²/day or 90 mg/kg/day.

Adverse Effect :

Vomiting, Anorexia, Diarrhea, Fever, Lethargy, Rash, Seizures, Ataxia, Encephalopathy, Somnolence, Depression, Nightmare, Impaired cognition, Hypertension.


Interaction :

Alcohol (Ethyl): May enhance the adverse/toxic effect of Cysteamine.
Antacids: May diminish the therapeutic effect of Cysteamine.
Histamine H2 Receptor Antagonists: May diminish the therapeutic effect of Cysteamine.
Proton Pump Inhibitors: May diminish the therapeutic effect of Cysteamine.



Hepatic Dose :

Use with caution. It is associated with reversible elevated transaminases.
08/26/2024 18:35:09 Cysteamine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0